1. Home
  2. SGMT vs RGCO Comparison

SGMT vs RGCO Comparison

Compare SGMT & RGCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SGMT
  • RGCO
  • Stock Information
  • Founded
  • SGMT 2006
  • RGCO 1912
  • Country
  • SGMT United States
  • RGCO United States
  • Employees
  • SGMT N/A
  • RGCO N/A
  • Industry
  • SGMT
  • RGCO Oil & Gas Production
  • Sector
  • SGMT
  • RGCO Utilities
  • Exchange
  • SGMT Nasdaq
  • RGCO Nasdaq
  • Market Cap
  • SGMT 269.2M
  • RGCO 236.2M
  • IPO Year
  • SGMT 2023
  • RGCO N/A
  • Fundamental
  • Price
  • SGMT $8.71
  • RGCO $22.00
  • Analyst Decision
  • SGMT Strong Buy
  • RGCO
  • Analyst Count
  • SGMT 8
  • RGCO 0
  • Target Price
  • SGMT $27.25
  • RGCO N/A
  • AVG Volume (30 Days)
  • SGMT 722.5K
  • RGCO 19.7K
  • Earning Date
  • SGMT 08-13-2025
  • RGCO 08-11-2025
  • Dividend Yield
  • SGMT N/A
  • RGCO 3.63%
  • EPS Growth
  • SGMT N/A
  • RGCO 5.90
  • EPS
  • SGMT N/A
  • RGCO 1.32
  • Revenue
  • SGMT N/A
  • RGCO $94,120,500.00
  • Revenue This Year
  • SGMT N/A
  • RGCO $10.87
  • Revenue Next Year
  • SGMT N/A
  • RGCO $3.26
  • P/E Ratio
  • SGMT N/A
  • RGCO $17.24
  • Revenue Growth
  • SGMT N/A
  • RGCO 12.04
  • 52 Week Low
  • SGMT $1.73
  • RGCO $19.06
  • 52 Week High
  • SGMT $11.41
  • RGCO $24.20
  • Technical
  • Relative Strength Index (RSI)
  • SGMT 55.77
  • RGCO 54.30
  • Support Level
  • SGMT $8.62
  • RGCO $20.62
  • Resistance Level
  • SGMT $10.06
  • RGCO $23.01
  • Average True Range (ATR)
  • SGMT 0.70
  • RGCO 0.70
  • MACD
  • SGMT -0.05
  • RGCO 0.23
  • Stochastic Oscillator
  • SGMT 58.06
  • RGCO 69.67

About SGMT Sagimet Biosciences Inc. Series A

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.

About RGCO RGC Resources Inc.

RGC Resources Inc is involved in the business of distribution and sale of natural gas to residential, commercial, and industrial customers within its service territory in Roanoke, Virginia, and its surrounding localities. The company also provides certain non-regulated services. The company relies on multiple interstate pipelines to transport natural gas. The company operates in three segments: Gas Utility, which is the key revenue generator; Investment in Affiliates this segment reflects the income generated through the activities of the Company's investment in MVP and Southgate projects and Parent & Other including the unregulated activities of the Company as well as certain corporate eliminations.

Share on Social Networks: